HCPCS Level II code J3380 designates vedolizumab supplied for intravenous injection, billed per 1 mg. As a biologic agent used in inflammatory bowel disease and related immune-mediated conditions, vedolizumab dosing and billing affect drug spend, infusion workflow, and payer coverage policies across the U.S. This code matters nationally because biologic drug costs drive significant outpatient specialty drug spending and require precise unit-based billing for claims processing and benefit management.

Key payers reviewed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how the code is used in practice, typical sites of service, and the clinical context surrounding vedolizumab therapy. The publication summarizes common billing considerations for unit-based HCPCS reporting, typical payer coverage patterns, and operational implications for infusion centers.

The report delivers benchmarks for utilization and reimbursement where available, outlines relevant policy updates affecting specialty drug billing and reimbursement, and provides clinical context on vedolizumab as an IV-administered biologic. Data not available in the input is noted where applicable.